Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ezetimibe

FDA-approved product (tablet, oral), marketed as Ezetimibe, Zetia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ezetimibe
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Familial hypercholesterolemia
  • Homozygous familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other lipid modifying agents
FDA pharmacologic class
Dietary Cholesterol Absorption Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ezetimibe in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ezetimibe with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

    NCT03847506 · start 2018-07-05

    Registered record
    Registry ID
    NCT03847506
    Conditions
    Hypertension, Hyperlipidemia
    Interventions
    Ezetimibe/Rosuvastatin; Candesartan cilexetil/Amlodipine besylate; Candesartan cilexetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-07-05
    Completion
    2020-12-02
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Hyperlipidemia
    InterventionEzetimibe/Rosuvastatin; Candesartan cilexetil/Amlodipine besylate; Candesartan cilexetil
    PhasePhase 4
    Registry statusCompleted

  • Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802

    NCT03532854 · start 2018-05-28

    Registered record
    Registry ID
    NCT03532854
    Conditions
    Healthy Male Volunteers
    Interventions
    Valsartan; Ezetimibe/Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-28
    Completion
    2019-01-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male Volunteers
    InterventionValsartan; Ezetimibe/Rosuvastatin
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.

    NCT04081844 · start 2018-05-03

    Registered record
    Registry ID
    NCT04081844
    Conditions
    Healthy
    Interventions
    HCP1306; HGP0904; HGP0608
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-03
    Completion
    2018-06-28
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionHCP1306; HGP0904; HGP0608
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin

    NCT04080310 · start 2018-03-15

    Registered record
    Registry ID
    NCT04080310
    Conditions
    Cardiovascular Diseases
    Interventions
    Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-15
    Completion
    2019-09-17
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases
    InterventionEfficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin
    PhasePhase 4
    Registry statusCompleted

  • A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

    NCT03337308 · start 2017-10-23

    Registered record
    Registry ID
    NCT03337308
    Conditions
    Hyperlipidemias
    Interventions
    Bempedoic Acid + Ezetimibe Fixed-Dose Combination; Bempedoic Acid; Ezetimibe; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-10-23
    Completion
    2018-07-18
    Enrolment
    382

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemias
    InterventionBempedoic Acid + Ezetimibe Fixed-Dose Combination; Bempedoic Acid; Ezetimibe; Placebos
    PhasePhase 3
    Registry statusCompleted

  • Anti-inflammatory Effects of Simvastatin

    NCT04638400 · start 2017-05-01

    Registered record
    Registry ID
    NCT04638400
    Conditions
    Inflammation; Atherosclerosis; Hypercholesterolemia
    Interventions
    Simvastatin 40mg; Ezetimibe 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-05-01
    Completion
    2021-11-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation; Atherosclerosis; Hypercholesterolemia
    InterventionSimvastatin 40mg; Ezetimibe 10mg
    PhasePhase 4
    Registry statusTerminated

  • Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

    NCT02984982 · start 2016-11-15

    Registered record
    Registry ID
    NCT02984982
    Conditions
    Hypercholesterolemia; Acute Coronary Syndrome
    Interventions
    Alirocumab SAR236553; Atorvastatin; Rosuvastatin; Fenofibrate; Bezafibrate; Ezetimibe; Antiplatelets; Anticoagulants
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-11-15
    Completion
    2018-07-27
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia; Acute Coronary Syndrome
    InterventionAlirocumab SAR236553; Atorvastatin; Rosuvastatin; Fenofibrate +4 more
    PhasePhase 4
    Registry statusCompleted

  • A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

    NCT02748057 · start 2016-05-18

    Registered record
    Registry ID
    NCT02748057
    Conditions
    Hypercholesterolemia; Familial Hypercholesterolemia
    Interventions
    Ezetimibe; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-05-18
    Completion
    2017-12-11
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia; Familial Hypercholesterolemia
    InterventionEzetimibe; Rosuvastatin
    PhasePhase 3
    Registry statusCompleted

  • to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers

    NCT02289430 · start 2014-12

    Registered record
    Registry ID
    NCT02289430
    Conditions
    Healthy
    Interventions
    Crestor+Ezetrol; Ezetrol; Crestor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-12
    Completion
    2015-02
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCrestor+Ezetrol; Ezetrol; Crestor
    PhasePhase 1
    Registry statusCompleted

  • The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients

    NCT02103049 · start 2014-04

    Registered record
    Registry ID
    NCT02103049
    Conditions
    Dyslipidemia; Transplants
    Interventions
    Ezetimibe
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia; Transplants
    InterventionEzetimibe
    PhasePhase 4
    Registry statusCompleted

  • Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis

    NCT01950884 · start 2013-10

    Registered record
    Registry ID
    NCT01950884
    Conditions
    •Non-alcoholic Steatohepatitis (NASH)
    Interventions
    Ezetimibe; Lifestyle
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-10
    Completion
    2014-12
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition•Non-alcoholic Steatohepatitis (NASH)
    InterventionEzetimibe; Lifestyle
    PhasePhase 4
    Registry statusUnknown

  • Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

    NCT01941836 · start 2013-09

    Registered record
    Registry ID
    NCT01941836
    Conditions
    Hypercholesterolemia
    Interventions
    ETC-1002; Ezetimibe
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09
    Completion
    2014-11
    Enrolment
    349

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionETC-1002; Ezetimibe
    PhasePhase 2
    Registry statusCompleted

  • Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study

    NCT01849068 · start 2013-06

    Registered record
    Registry ID
    NCT01849068
    Conditions
    Metabolic Syndrome X
    Interventions
    Ezetimibe; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome X
    InterventionEzetimibe; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

    NCT01420549 · start 2013-03

    Registered record
    Registry ID
    NCT01420549
    Conditions
    Hypercholesterolemia; Dyslipidemia
    Interventions
    Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.; Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03
    Completion
    2014-11
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia; Dyslipidemia
    InterventionRosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.; Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

    NCT01370590 · start 2011-09

    Registered record
    Registry ID
    NCT01370590
    Conditions
    Hypercholesterolemia
    Interventions
    Atorvastatin; Ezetimibe; Ezetimibe/atorvastatin; Placebo to atorvastatin; Placebo to ezetimibe; Placebo to ezetimibe/atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2012-04
    Enrolment
    406

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionAtorvastatin; Ezetimibe; Ezetimibe/atorvastatin; Placebo to atorvastatin +2 more
    PhasePhase 3
    Registry statusCompleted